The widely-used statin drugs, which increase levels of serum ApoA-I through inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase [29], have had a significant therapeutic benefit by reducing the risk for cardiomyopathy [30] and heart failure [31]. This evidence concerns the gene APOA1 and cardiomyopathy.